Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK

被引：0
|
作者：
Alex Diamantopoulos
A. Finckh
T. Huizinga
D. K. Sungher
L. Sawyer
D. Neto
F. Dejonckheere
机构：
[1] Symmetron Limited,Rheumatology
[2] Kinetic Centre,Rheumatology
[3] University Hospitals of Geneva,undefined
[4] Leiden University Medical Center,undefined
[5] F. Hoffmann-La Roche,undefined
来源：
PharmacoEconomics | 2014年 / 32卷
关键词：
Palliative Care; Juvenile Idiopathic Arthritis; Tocilizumab; Visual Analogue Scale Pain; Health Assessment Questionnaire;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：775 / 787
页数：12
相关论文
共 50 条
  • [1] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Diamantopoulos, Alex
    Finckh, A.
    Huizinga, T.
    Sungher, D. K.
    Sawyer, L.
    Neto, D.
    Dejonckheere, F.
    PHARMACOECONOMICS, 2014, 32 (08) : 775 - 787
  • [2] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS, IN COLOMBIA
    Gamboa, O.
    Barbosa, D.
    Parada, L.
    Latorre, M.
    VALUE IN HEALTH, 2013, 16 (07) : A563 - A563
  • [3] COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    Erdogan-Ciftci, E.
    Celik, H.
    Orfanos, P.
    VALUE IN HEALTH, 2018, 21 : S295 - S295
  • [4] COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB WITHOUT METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    Erdogan-Ciftci, E.
    Celik, H.
    Orfanos, P.
    VALUE IN HEALTH, 2018, 21 : S297 - S297
  • [5] Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran
    Metghalchi, Yalda
    Yaghoubi, Neda
    Yousefi, Nazila
    Ahmadi, Razieh
    Kargar, Alireza
    Zargaran, Marzieh
    Rezaei, Soheila
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2024, 22 (01):
  • [6] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB VERSUS INFLIXIMAB FOR THE PATIENTS WITH RHEUMATOID ARTHRITIS IN KAZAKHSTAN
    Bektur, C.
    Kayir, F.
    Nurgozhin, T.
    VALUE IN HEALTH, 2014, 17 (07) : A379 - A379
  • [7] COST-EFFECTIVENESS ANALYSIS OF GOLIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Desai, R. J.
    Rao, J.
    Biddle, A. K.
    VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
  • [8] THE COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRA™) IN PATIENTS WITH RHEUMATOID ARTHRITIS: A UK ANALYSIS
    Bansback, N.
    Brennan, A.
    Sengupta, N.
    Pang, F.
    RHEUMATOLOGY, 2004, 43 : 77 - 77
  • [9] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SUBCUTANEOUSCOMBOTHERAPY FIRST LINE FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS IN GREECE
    Athanasakis, K.
    Tarantilis, F.
    Skroumpelos, A.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2016, 19 (07) : A538 - A538
  • [10] COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE MANAGEMENT OF INADEQUATELY RESPONDING RHEUMATOID ARTHRITIS PATIENTS
    Hansen, R. N.
    Best, J. H.
    Sullivan, S. D.
    Carlson, J. J.
    VALUE IN HEALTH, 2015, 18 (03) : A161 - A161
12345